実臨床における体軸型脊椎関節炎の継続率に 関連する因子: レトロスペクティブ研究結果(FORSYA)
RMD Open 2023;9:e002802 doi: 10.1136/rmdopen-2022-002802
This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.